Startups
Instil Bio is a cell therapy company developing tumor infiltrating lymphocytes (TIL) for the treatment of solid tumor cancers. TIL are a patient’s own T cells harvested from the patient’s tumor, which are then expanded and reinfused into the patient to target and kill cancer cells. The company is advancing its proprietary manufacturing expertise, technology, and data into clinical trials, including a planned registrational study with its lead candidate and a first-in-human study of its next-generation engineered TIL. The company is led by world-class cell therapy experts and backed by premier global institutional investors. Instil is located in the greater Los Angeles area with additional manufacturing and research facilities in Manchester, UK.
Overview
Location
United States
Employees
201-500
Founded date
2018
Investors 3
| Date | Name | Website |
| Sign up to see | Sign up to see | Sign up to see |
| Vivo Capital | vivocapital.com | |
| HBM Partners | hbmpartners.com |
Mentions in press and media 9
| Date | Title | Description |
| Sign up to see | Sign up to see | Sign up to see |
| Oct 18, 2022 | Instil Bio Announces First Patient Dosed with ITIL-306, our First Engineered TIL Therapy Using the CoStAR Platform Targeting Folate Receptor Alpha (FRα), in Non-Small Cell Lung Cancer | • ITIL-306 is a novel TIL therapy engineered with our CoStAR platform (CoStAR-TIL) targeting folate receptor alpha which is designed to boost TIL activity in the tumor microenvironment • CoStAR-T cells demonstrate enhanced proliferation and... |
| Sep 6, 2022 | Instil Bio Announces Appointment of Tim Moore as Chief Operating Officer | DALLAS, Sept. 06, 2022 (GLOBE NEWSWIRE) -- Instil Bio, Inc. (“Instil”) (NASDAQ: TIL), a clinical-stage biopharmaceutical company focused on developing tumor infiltrating lymphocyte, or TIL, therapies for the treatment of patients with cance... |
| Aug 12, 2022 | Instil Bio Reports Second Quarter 2022 Financial Results and Provides Corporate Update | Cash runway expected to extend from 2024 into 2025 upon completion of anticipated sale-leaseback of Tarzana, CA manufacturing site DELTA-1 trial of ITIL-168 in advanced melanoma with registrational intent anticipated to complete enrollment ... |
| May 27, 2022 | Instil Bio Announces IND Clearance of First CoStAR-TIL program, ITIL-306, Designed to Enhance Activity in the Tumor Microenvironment | FDA granted IND clearance for ITIL-306, Instil’s first genetically-engineered CoStAR-TIL therapy for the treatment of NSCLC, RCC, and ovarian cancer Instil to present in vivo data with CoStAR T cells demonstrating enhanced expansion, persis... |
| May 18, 2022 | Instil Bio to Present Novel TIL Analytics at American Society of Gene and Cell Therapy (ASGCT) | DALLAS, May 18, 2022 (GLOBE NEWSWIRE) -- Instil Bio, Inc. (“Instil”) (Nasdaq: TIL), a clinical-stage biopharmaceutical company focused on developing tumor infiltrating lymphocyte, or TIL, therapies for the treatment of patients with cancer,... |
| May 16, 2022 | Instil Bio Reports First Quarter 2022 Financial Results and Provides Corporate Update | Targeting completion of enrollment in registrational cohort of DELTA-1 in 2022Presenting preclinical efficacy and safety data of CoStAR platform at ASCO 2022Cash runway into 2024 through key clinical data expected in 2023 DALLAS, May 16, 20... |
| Mar 19, 2021 | Instil Bio’s upsized IPO raises $320M for clinical tests of TIL cancer cell therapy | Instil was able to sell more shares and at a higher price than it initially planned. The Dallas-based company set preliminary IPO terms on Monday for an offering of 13.9 million shares in the range of $17 to $19 each. On Thursday, the biote... |
| Instil Bio’s upsized IPO raises $320M for clinical tests of TIL cancer cell therapy | The cell therapy technology that underpins Instil Bio has treated fewer than two dozen patients in the past decade—all of them under compassionate use. In the three years since the cancer drug developer launched, it has leveraged the limite... |
Reviews 0
FAQ about Instil Bio
When was Instil Bio founded?
Instil Bio was founded in 2018.
Who has invested in Instil Bio?
Parsers VC lists 3 investors of Instil Bio, among them Vivo Capital and HBM Partners.
What has the press written about Instil Bio?
Parsers VC has collected 9 articles mentioning Instil Bio, among them “Instil Bio Announces First Patient Dosed with ITIL-306, our First Engineered TIL Therapy Using the CoStAR Platform Targeting Folate Receptor Alpha (FRα), in ...” (Oct 18, 2022) and “Instil Bio Announces Appointment of Tim Moore as Chief Operating Officer” (Sep 6, 2022).
Is Instil Bio still active?
Yes, Instil Bio is active; its latest activity on Parsers VC dates from Oct 31, 2022.